Atrium Therapeutics, Inc. Common Stock · RNA

Exhibit 99.1 Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 - ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation of cardiac glycogen and cardiac hypertrophy - - Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndrome - - Poster presentation November 6 at 5:30 p.m. CT - SAN DIEGO, Nov. 2, 2026 - Atrium T…

8-K · 2026-11-02 · 0001193125-26-442601

Exhibit 99.2 Atrium Therapeutics 2 November 2026 RNA L I S T E D www.atriumtherapeutics.com NASDAQ 1 Forward-Looking Statements Forward - Looking Statements FORWARD LOOKING STATEMENTS AND OTHER INFORMATION: Certain statements in this Presentation may constitute “forward -looking statem ents” for purposes of the federal securities laws. Our forward -looking statements include, but are not limited to, statements regarding our future results of operations and financial position, including our exp …

8-K · 2026-11-02 · 0001193125-26-442601

Exhibit 99.1 Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome - Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants - - Initial proof of concept data expected in second half of 2027 - SAN DIEGO, Oct. 27, 2026 - Atrium Therapeutics, Inc. (Nasdaq: RNA) (the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, tod…

8-K · 2026-10-27 · 0001193125-26-432949

Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO R…

8-K · 2026-10-08 · 0001193125-26-417402

Exhibit 99.1 Atrium Therapeutics Announces $50 Million Private Placement SAN DIEGO, October 8, 2026 - Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the “purchase agreement”) with a group of leading institutional investors for a private placement financing (the “private placement”). The p…

8-K · 2026-10-08 · 0001193125-26-417402

EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results - IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome - - Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb - SAN DIEGO, August 13, 2026 / PRNewswire/ - Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics,” or the “Company”), a biopharmaceutical company advanc…

8-K · 2026-08-13 · 0001193125-26-349482